256 related articles for article (PubMed ID: 23510764)
21. The impact of cytology screening and HPV vaccination on the burden of cervical cancer.
Tay K; Tay SK
Asia Pac J Clin Oncol; 2011 Jun; 7(2):154-9. PubMed ID: 21585695
[TBL] [Abstract][Full Text] [Related]
22. Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination.
Dillner J; Arbyn M; Dillner L
Clin Exp Immunol; 2007 May; 148(2):199-207. PubMed ID: 17437418
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
24. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
Van Minh H; My NTT; Jit M
BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
[TBL] [Abstract][Full Text] [Related]
25. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1382-4. PubMed ID: 21993342
[TBL] [Abstract][Full Text] [Related]
26. Will HPV vaccination affect cervical cancer morbidity and mortality world-wide?
Luckett R; Feldman S
Hum Vaccin Immunother; 2016 Jun; 12(6):1373-4. PubMed ID: 27104494
[No Abstract] [Full Text] [Related]
27. [Expert consensus on immunological prevention of human papillomavirus-related diseases].
Vaccine and Immunization Branch, Chinese Preventive Medicine Association
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Aug; 53(8):761-803. PubMed ID: 31378039
[TBL] [Abstract][Full Text] [Related]
28. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus vaccines: who will pay, who will receive, when to administer?
Saslow D; Wheeler CM
Ethn Dis; 2007; 17(2 Suppl 2):S2-8-13. PubMed ID: 17684807
[TBL] [Abstract][Full Text] [Related]
30. Global Delivery of Human Papillomavirus Vaccines.
Wigle J; Fontenot HB; Zimet GD
Pediatr Clin North Am; 2016 Feb; 63(1):81-95. PubMed ID: 26613690
[TBL] [Abstract][Full Text] [Related]
31. HPV genotypes: implications for worldwide cervical cancer screening and vaccination.
Wheeler CM
Lancet Oncol; 2010 Nov; 11(11):1013-4. PubMed ID: 20952255
[No Abstract] [Full Text] [Related]
32. Promoting the immunization neighborhood: Benefits and challenges of pharmacies as additional locations for HPV vaccination.
Rothholz M; Tan LLJ
Hum Vaccin Immunother; 2017 Aug; 13(8):1856-1858. PubMed ID: 27216035
[No Abstract] [Full Text] [Related]
33. Can male vaccination reduce the burden of human papillomavirus-related disease in the United States?
Low GM; Attiga YS; Garg G; Schlegal R; Gallicano GI
Viral Immunol; 2012 Jun; 25(3):174-86. PubMed ID: 22691099
[TBL] [Abstract][Full Text] [Related]
34. HPV vaccination: Clinical potential, implementation challenges, and future directions.
Perkins RB
Hum Vaccin Immunother; 2016 Jun; 12(6):1327-31. PubMed ID: 27294609
[No Abstract] [Full Text] [Related]
35. Controlling cervical cancer.
Bonati M; Garattini S
Pharmacoeconomics; 2009; 27(2):91-3. PubMed ID: 19254043
[No Abstract] [Full Text] [Related]
36. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
[TBL] [Abstract][Full Text] [Related]
37. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
38. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
Lehtinen M; Apter D
Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
[TBL] [Abstract][Full Text] [Related]
39. [Expert consensus on immunological prevention of human papillomavirus-related diseases (abridged)].
Vaccine and Immunization Branch, Chinese Preventive Medicine Association
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Dec; 40(12):1499-1516. PubMed ID: 32062907
[TBL] [Abstract][Full Text] [Related]
40. The new HPV vaccination.
Bedford H
Community Pract; 2008 Aug; 81(8):36-7. PubMed ID: 18834017
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
